Telix Pharmaceuticals |
Market Cap (5-Aug) $4,881,777,152 (204th) |
Close (30-Jun) $11.22 |
Volume (30-Jun) 664,557 |
Shortsold (30-Jul) 39,831,980 (11.72%) (8th) |
|
52w High $19.07 |
52w Low $8.26 |
P/E 250.00 |
EPS -0.03 |
[ARTICLE] Fund managers back market darling Telix Pharmaceuticals
A news article has been posted about Telix Pharmaceuticals on the AFR. The article was published around , on 4 August 2022 at 3:38pm.
A bevvy of healthcare analysts and Australian equities managers have profited from buying fast-rising oncology business Telix, after it unveiled strong sales.
Read ArticleTLX was $7.42 at the close of trade on 03 August 2022
| Recent Articles about ASX:TLX | |
|---|---|
| 21-Jul | Notice of change of interests of substantial holder - AFR
company-announcements.afr.com |
| 21-Jul | Q2 Business Update - Telix Pharmaceuticals Limited
company-announcements.afr.com |
| 19-Jul | Appendix 3H - Notification of cessation of securities - AFR
company-announcements.afr.com |
| 17-Jul | Appendix 3G - Notification of issue, conversion or payment up ... - AFR
company-announcements.afr.com |
| 4-Jul | Q1 2026 Strong Revenue Growth and Tx Pipeline Advancement
company-announcements.afr.com |
| 3-Jul | 604 Page 1 of 6 - Market Index
company-announcements.afr.com |
| 3-Jul | Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain ...
company-announcements.afr.com |
| 2-Jul | FDA Alignment to Advance ProstACT Global Phase 3 Trial - AFR
company-announcements.afr.com |
| 1-Jul | Notice of change of interests of substantial holder - AFR
company-announcements.afr.com |
| 23-Jun | Notice of ceasing to be a substantial holder - AFR
company-announcements.afr.com |
| Tracked |
Find all articles about Telix Pharmaceuticals, including others on the AFR, on the media page.
You must be logged in to post a reply.